Core Insights - Huaxi Biological reported its worst half-year results, with revenue of 2.261 billion yuan, a year-on-year decline of 19.57%, and a net profit of 221 million yuan, down 35.38% [1][2] - The company is undergoing significant reforms, with 2024 designated as the "Year of Transformation," and management changes aimed at accelerating strategic implementation [1][4] - The decline in performance is attributed to a significant drop in the skin science innovation business, which saw revenue decrease by 33.97% to 912 million yuan, accounting for 40.36% of total revenue [2][4] Business Performance - The core skin science innovation business has been a major drag on overall performance, with revenue from this segment declining for the second consecutive year [2][4] - Other business segments, including raw materials and medical terminal businesses, also experienced declines, with raw materials revenue slightly down by 0.58% and medical terminal revenue down by 9.44% [4] - R&D projects decreased by 88 compared to 2024, with a focus on raw materials and medical terminal businesses, although new product launches have not yet contributed to revenue growth [4] Management Changes - The company underwent a significant management overhaul, with 11 executives leaving during the reporting period, leading to increased management costs of approximately 29 million yuan [4] - A new board of directors was elected on June 11, 2025, as part of the organizational restructuring aimed at long-term development [4] Legal Issues - Huaxi Biological's wholly-owned subsidiary, Julang Co., has initiated international arbitration against South Korean biopharmaceutical company Medytox, claiming damages of up to 750 million HKD due to contract violations [5]

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company has shown significant improvement in profits in Q2 2025, with a notable recovery in net profit compared to Q1 2025 [1][10]. - The chairman's active involvement in management is expected to drive positive changes in the company's performance in the second half of the year [10]. - The company is undergoing a transformation towards an "efficiency-oriented" approach, which has led to a significant reduction in sales expense ratios [9][10]. Financial Performance Summary - For the first half of 2025, the company reported revenues and net profits of 2.26 billion and 220 million yuan, respectively, reflecting year-on-year declines of 19.6% and 35.4% [4]. - Q2 2025 saw revenues and net profits of 1.18 billion and 120 million yuan, with a year-on-year decline of 18.4% in revenue but a 20.9% increase in net profit [4]. - The company's gross margin for the first half of 2025 was 71.0%, down 3.5 percentage points year-on-year [8]. Business Segment Performance - The raw materials segment showed resilience, with revenue of 630 million yuan, a slight decline of 0.6% year-on-year, while the medical terminal products segment generated 670 million yuan, down 9.4% [5]. - The skin science innovation transformation business experienced a significant decline of 34.0% in revenue, totaling 910 million yuan, while the nutrition science innovation transformation business grew by 32.4% to 40 million yuan [5]. - The company launched several new medical aesthetic products in 2025, contributing to a diversified product matrix [6]. Market Outlook - The company is expected to return to a positive growth trajectory, with revenue forecasts adjusted to 4.825 billion, 5.631 billion, and 6.735 billion yuan for 2025, 2026, and 2027, respectively [11]. - The report anticipates that the company's earnings per share (EPS) will be 0.98, 1.23, and 1.66 yuan for 2025, 2026, and 2027, respectively [11]. - The chairman's plan to increase shareholding by 200 to 300 million yuan within six months reflects confidence in the company's future development [11].

Core Viewpoint - Huaxi Biological, a leading hyaluronic acid company, continues to face pressure on its performance, with significant declines in revenue and net profit in the first half of 2025 [1] Financial Performance - In the first half of 2025, Huaxi Biological reported revenue of 2.261 billion yuan and a net profit attributable to shareholders of 221 million yuan, representing year-on-year declines of 19.57% and 35.38% respectively [1] - In the second quarter, the company's revenue was 1.183 billion yuan, down nearly 20% year-on-year [2] - The skincare innovation business, a key revenue driver, generated 912 million yuan, experiencing a decline of over 30% year-on-year [2] Industry Comparison - The company's performance significantly lags behind the industry, with China's cosmetic retail sales reaching 229.1 billion yuan in the first half of 2025, a year-on-year growth of 2.9% [3] - Competitors such as Proya and Shuiyang reported nearly 10% year-on-year revenue growth during the same period [3] Cost Management - Huaxi Biological has significantly reduced its sales expenses, which amounted to 808 million yuan in the first half of 2025, down 31.44% year-on-year, accounting for 35.74% of revenue, a decrease of over 6 percentage points [3] - The company has ceased price promotion campaigns on various platforms, aiming to restructure its brand's technical foundation for better customer acquisition models [3] Business Strategy - The company is adopting a "price-for-volume" strategy to boost sales of its medical beauty products, with medical product revenue at 467 million yuan, down 1.8% year-on-year, while sales of three types of medical devices increased by 20% [3] - Huaxi Biological plans to optimize its product structure and channel layout to adapt to market changes [4] Brand Development - The medical beauty brands "Run Bai Yan" and "Run Zhi" have been launched on the Meituan medical beauty platform to enhance user reach [6] - The chairman of Huaxi Biological, Zhao Yan, has returned to frontline operations to boost performance, although the effectiveness of these reforms may take more time to manifest [6]

对话头部医美机构专家 - 探索行业需求新方向 20250827 摘要 4 毫克提纯胶原蛋白仍是使用量最大的品类，但增速放缓，预计 2025 年增速约为 15%，低于去年的 61%，而 10 毫克、17 型等胶原蛋白品 类增长较快。 Q&A 最近医美行业的营收和客流情况如何？ 7 月份的营收增速有所放缓，客流量增速保持在 8%左右，但客单价持续下降。 8 月份的具体业绩尚未统计完全，但从目前数据来看，客流量增速也有所放缓， 预计营收与去年相比基本持平或略有下降。整体来看，8 月份的表现不太理想。 手术类和非手术类项目的表现如何？ 手术类整形外科项目，包括手术量和客流量，都出现了明显下滑，占比也有所 下降。非手术类项目，如光电治疗等，虽然影响较小，但客流量增速仅在 2-3 个百分点左右，与去年同比基本持平甚至略有下降。今年 1-7 月，不论是客流、 营收还是单价，都受到了较大影响。 医美行业整体市场表现如何？是否存在竞争压力？ 2025 年 8 月医美市场整体表现不佳，手术类项目下滑明显，非手术类 项目增速放缓，行业营收增长面临挑战，预计与去年同期持平，难以实 现 5%以上增长。 机构通过 8 月底至 9 月中旬 ...

8月22日，美团发布2025北极星医美榜，全国共有39个城市的152家医美机构和来自26个城市的240位医 生上榜，通过927项专业考察点、专家评审团及大规模用户调研，为消费者提供权威的医美机构与医生 选择指南。 在美团北极星医美榜2025年发布会上，首批上榜的香港机构YM逸苗医疗医美部、香港DR REBORN医 学美容代表现场接受颁奖。YM逸苗医疗医美部的首席执行官及创办人许国城表示："很荣幸入选美团 北极星医美榜，这是对我们医疗医美质量与服务的双重认可。通过美团平台，我们期待接触更广泛的客 户群体。" 美团医美进入港澳市场两年来发展迅速，目前平台已汇聚460家优质医疗医美机构，覆盖香港、澳门主 要商业区。通过本地化运营，平台不仅提供机构信息查询、在线咨询预约、在线成交等基础服务，美团 还致力于帮助机构进行经营数字化、服务专业化的能力建设，实现长期经营。今年将全新推出AI导购 助手、AI咨询师等，用技术能力帮助商户经营提效。除此之外，美团还将开放平台能力，提供新的上 游采销模式，帮助机构提效降本，实现更轻松运营。 美团医美成功构建了连接香港优质医美资源与内地庞大消费市场的桥梁，丰富了求美者的变美选择，让 香 ...

Core Viewpoint - The signing of the China-Japan-South Korea Free Trade Agreement (FTA) is crucial for addressing common challenges and enhancing regional economic integration, which is a strategic choice in the context of changing global geopolitical and economic landscapes [1][2][3] Economic Cooperation and Trade Dynamics - China, Japan, and South Korea are at a critical juncture in their economic cooperation, with intra-regional trade declining from approximately $850 billion in 2021 to about $737 billion in 2024, a decrease of 13.5% [2] - The trade dependency ratio among the three countries has fallen from 19.4% to 16.5%, significantly lower than that of the EU (65.7%) and North America (40.1%) [2] Importance of FTA Negotiations - Accelerating FTA negotiations is seen as a wise move to avoid the agreement becoming irrelevant, similar to past experiences with the EU [3] - The combined GDP of China, Japan, and South Korea accounts for 24% of the global total, and their trade volume represents about 20% of global trade, contributing 70% of Asia's economic growth and 36% of global economic growth [3] Potential Economic Impact - The FTA could lead to a GDP increase of 0.3% to 1.1% for the three countries [4] - The service trade sector is becoming increasingly important, with the total service trade volume of the three countries exceeding $1.63 trillion, highlighting the need for cooperation in this area [5] Service Trade Opportunities - Digital services are among the fastest-growing sectors, with China's digital service exports reaching $366.6 billion in 2023, a 3.5% increase [6] - There is significant potential for cooperation in areas such as cross-border data processing, digital healthcare, and smart manufacturing services [7] Regional Economic Integration - The FTA is expected to play a leading role in upgrading the Regional Comprehensive Economic Partnership (RCEP) from its current 1.0 version to a higher level [9][10] - The RCEP is currently at a critical point of transition, with the service trade import and export volumes in the region showing substantial growth from 2011 to 2023 [10] Future Market Dynamics - By 2024, the combined economic scale of China, Japan, and South Korea is projected to reach $24.64 trillion, representing 22.13% of the global economy and 80.43% of the RCEP region [11] - The FTA could facilitate the establishment of high-level economic rules in areas such as digital economy and intellectual property, supporting the creation of a unified regional market [11]

调研行业： 参与调研的机构：投资者网上提问等 敷尔佳分析师会议 调研日期：2025年08月26日 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START SHILL CARD | | | 颜的集团 | ...

Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2025, with total revenue at 2.261 billion yuan, down 19.57% year-on-year, and net profit attributable to shareholders at 221 million yuan, down 35.38% [1] - The decline in revenue is primarily attributed to a decrease in the skin science innovation transformation business, which saw a revenue drop of 33.97% [1] Revenue Breakdown - The raw material business generated revenue of 626 million yuan, a slight decrease of 0.58%, accounting for 27.70% of the company's main business revenue [1] - The medical terminal business reported revenue of 673 million yuan, down 9.44%, representing 29.77% of the main business revenue [1] - The skin science innovation transformation business earned 912 million yuan, down 33.97%, making up 40.36% of the main business revenue [1] - The nutrition science innovation transformation business, under Huaxi Dangkang, achieved revenue of 38 million yuan, an increase of 32.40% [1] Product Portfolio - The company offers medical beauty products under two main brands, "Runbaiyan" and "Runzhi," covering a range of applications from skin care to layered anti-aging [2] - The core brand Runzhi has launched multiple products targeting different skin layer needs, including Runzhi Natural, No. 2, No. 3, No. 5, Feiran Needle, and Yaoran Needle [2] - The company has developed a matrix of compliant skin care products based on in-depth research of extracellular matrix (ECM) effects on aging, including Runbaiyan·Glass, Runzhi·Tito, Runzhi·Gege, and Runzhi Doll Needle [2] - Runzhi Zhenhuo(®) is marketed for post-operative skin care, providing a comprehensive solution to enhance customer and consumer satisfaction through a diverse product series [2]

Core Viewpoint - The article discusses the challenges faced by the company, Xinyang, as it transitions from an online medical beauty platform to a physical clinic model, highlighting the financial struggles and competitive pressures from larger platforms like Meituan and Douyin [4][10][15]. Financial Performance - In Q2 2025, Xinyang reported total revenue of 379 million yuan, a year-on-year decline of 7.0%, and a net loss of 36 million yuan compared to a net profit of 18.9 million yuan in the same period of 2024 [4]. - The total cost for Q2 2025 was 184.6 million yuan, up 19.0% from 155.1 million yuan in the previous year [4]. - Revenue from Xinyang's core business, "Information and Appointment Services," fell to 929 million yuan in 2024, a decrease of 19.36%, accounting for 63.37% of total revenue [10][11]. Business Transition - Xinyang launched its self-operated chain of clinics, SOYOUNG CLINIC, in November 2024, with 33 locations by August 2025, aiming for 50 by year-end [5][6]. - The shift to physical clinics has led to increased competition with former clients, resulting in further declines in online business [7][8]. Competitive Landscape - Xinyang faces significant competition from Meituan, which opened nearly 3,000 new medical beauty institutions in 2024, and Douyin, which has implemented various support policies for medical beauty services [13][14]. - The competition has led to a decrease in the number of medical service providers on Xinyang's platform, impacting its revenue [11][13]. Growth of Clinic Business - The chain business generated 170 million yuan in revenue in 2024, a staggering increase of 1,206%, with Q4 revenue reaching 81.27 million yuan, up 702% [15]. - The introduction of low-priced services, such as the "童颜针" (Youthful Needle), significantly boosted Xinyang's stock price, which rose 223% in a short period [15][16]. Operational Challenges - Rapid expansion of the clinic model has led to financial burdens, particularly in second-tier cities where patient volumes are lower [20]. - The average gross margin of 24% for the clinic business is considered unsatisfactory, and the CEO acknowledged the ongoing financial losses due to the clash between new and old business models [20][21]. Customer Dynamics - The dual role of Xinyang as both a platform and a service provider raises concerns about potential conflicts of interest and customer retention [23][24]. - While the clinic's standardized operations and competitive pricing are seen as strengths, there are concerns about the quality of service and customer satisfaction [26][27]. Industry Trends - The medical beauty industry is experiencing a slowdown, with a report indicating that 57% of consumers plan to maintain or increase their spending in 2025, down from 78% in 2024 [28].

Group 1: Industry Trends - The medical beauty industry is experiencing a shift in promotional boundaries, with increased visibility through media such as the variety show "Actors Please Stand By 3" and the urban drama "In the Name of Beauty" [1][10] - The industry is facing a slowdown, with the annual compound growth rate expected to decrease from over 18.3% (2015-2024) to 13.2% in the next five years [2] - Consumer behavior shows a trend of maintaining budget while seeking better service and results, with a notable increase in repurchase frequency from 90 days last year to 64.3 days this year for Meituan's medical beauty users [2][4] Group 2: Meituan's Strategies - Meituan is enhancing its medical beauty business by launching the "North Star Medical Beauty List," which evaluates institutions and doctors based on 927 assessment points, providing reliable references for consumers [3][4] - The company has opened nearly 9,500 new medical beauty institutions on its platform this year [5] - Meituan is addressing the cost challenges faced by small and medium-sized institutions by collaborating with upstream brands to lower procurement costs [6][7] Group 3: Targeting High-End Consumers - Meituan is focusing on penetrating higher-tier consumer segments, particularly those classified as platinum and above, by offering special benefits and free services [8] - The company is leveraging external channels, such as sponsoring media content and utilizing platforms like Xiaohongshu, to attract higher spending users [9][10] - The recent relaxation of promotional boundaries in the medical beauty sector provides Meituan with broader opportunities for outreach and brand promotion [10]